NEW YORK, July 3, 2026, 10:05 EDT
- Nasdaq will be shut Friday for the Independence Day holiday. SLBT will trade next on Monday, July 6.
- SL Science NASDAQ:SLBT ended Tuesday at $5.99, climbing 34.6%. Volume hit 1.22 million shares.
- Shares jumped 59.7% in the past five sessions, according to WSJ/FactSet closing data.
- The company’s market cap is $3.36 billion, about 1,529 times the 2025 revenue estimate, according to market and company data.
SL Science Holding Limited NASDAQ:SLBT closed the U.S. holiday-shortened week on a strong move, but with a $3.36 billion market cap and just $2.20 million expected 2025 revenue, valuation remains a sticking point. Nasdaq is closed Friday for the Independence Day holiday after listing July 3, 2026, as a closure on its .
The last regular session saw the stock close at $5.99, a jump of $1.54, or 34.61%. The shares moved between $4.30 and $6.25, with 1.22 million traded. Google Finance had it at $5.76 after hours, off 3.84%.
The company’s news site last posted about June 19 results and the June 15 Nasdaq debut. There was no new update explaining the stock’s late-week surge.
The last five regular closes, per WSJ/FactSet:
| Session | Close | Move from prior close | Volume |
|---|---|---|---|
| June 26 | $3.75 | — | 115,024 |
| June 29 | $3.40 | -9.3% | 221,057 |
| June 30 | $4.79 | up 40.9% | 953,879 |
| July 1 | $4.45 | down 7.1% | 284,651 |
| July 2 | $5.99 | up 34.6% | 1.22 million |
After two strong sessions, the stock climbed 59.7% from where it closed on June 26. Turnover on Thursday was 43.6% of the volume across five days. The shares are still down 58.7% from the 52-week high of $14.50, according to Google Finance.
The valuation gap is the simpler play for investors here. SL Science posted a 35% drop in 2025 revenue to $2.197 million. Net loss widened to $3.821 million, while cash and restricted cash at year-end totaled $1.26 million. The company reported no revenue from its CD-19 Armed-T or GDT cell therapy units in 2025—sales came only from exosome products.
| Measure | Company or market figure | Read-through at July 2 close |
|---|---|---|
| Market cap | $3.36 billion | Based on current trading price |
| June merger implied equity value | $5.568 billion | Company is now trading at roughly 60.3% of that |
| 2025 revenue | $2.197 million | Market cap is about 1,529 times this revenue |
| 2025 net loss | $3.821 million | Net loss runs about 1.7 times expected revenue |
| Dec. 31 cash plus restricted cash | $1.26 million | Market value is about 2,667 times this cash |
| PIPE financing closed with deal | $7.8 million | Market cap works out to about 431 times the PIPE |
Horizon Space Acquisition II Corp. NASDAQ:HSPT wrapped up its merger with SLBT in June, Nasdaq Trader said. Horizon’s shares, rights, and units on Nasdaq were halted starting June 15, with SLBT taking over as the listed stock. Holders got one SLBT share for each Horizon share and one SLBT share for every 10 rights.
SL Science said the deal gave it an implied equity value of roughly $5.568 billion and included a $7.8 million PIPE. Chairman and CEO William Wang said the company will focus on “standardization and scalable manufacturing” for cell therapy. GlobeNewswire
SL Science is pushing key milestones out past next week. The company said it expects a Pre-IND meeting and an IND filing for CD-19 Armed-T in Q1 2027. Its GDT platform is shooting for an IND in Q3 2027. Wang said moving from retail sales to corporate distribution let the company focus more on its therapeutic work.
Speculative healthcare stocks moved up Thursday, getting some lift from the broader market, even though the Nasdaq slipped. The Dow added 1.1%, S&P 500 was little changed, Nasdaq fell 0.8%, Reuters said. U.S. trading will be closed on Friday. “The weak jobs report takes the pressure off the Fed to raise rates in the short term,” Adam Sarhan, CEO at 50 Park Investments, told Reuters. Reuters
Heading into Monday’s open, public price target data was missing. Google Finance said “No analyst ratings found,” while WSJ/FactSet didn’t show any analyst targets or ratings for the stock. Google
